"Hematology has become a major focus for Sanofi, and we are very excited about the progress we are making in advancing research on a relatively broad range of potential new treatments for people with rare blood disorders and blood cancers," said Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, the specialty care global business unit of Sanofi. "We look forward to sharing that progress with the hematology community at this year’s ASH meeting."
Advancements in Cancer (Hematological Malignancies)Data presented at ASH include the latest research regarding isatuximab, an anti-CD38 monoclonal antibody in late-stage development for patients with multiple myeloma, a rare plasma cell malignancy with high unmet medical need. Isatuximab is currently being investigated in four Phase 3 clinical trials, including three company sponsored pivotal trials.
Multiple Myeloma Oral Presentations at ASH:
- Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (abstract 155; oral presentation on Saturday, December 1, 2018: 12:00-1:30 PM (PT))
- Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant (abstract 595; oral presentation on Monday, December 3, 2018: 7:00-8:30 AM (PT))
Advancements in Rare Blood DisordersSanofi’s increased commitment to the rare blood disorders community follows the acquisition of two companies, Bioverativ and Ablynx, earlier this year. Sanofi will create a Rare Blood Disorders franchise in early 2019 that will become part of Sanofi Genzyme. In addition to two marketed therapies for the treatment of hemophilia, Sanofi’s pipeline includes novel investigational therapies in hemophilia, sickle cell disease(1), cold agglutinin disease and aTTP, a rare blood-clotting disorder.
Key Hemophilia Presentations at ASH:
- BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer (abstract 636; oral presentation on Monday, December 3, 2018: 10:30 AM-12:00 PM (PT)) (2)
- ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A (abstract 1192; poster on Saturday, December 1, 2018: 6:15-8:15 PM (PT)) (3)
- B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B (abstract 1214; poster on Saturday, December 1, 2018: 6:15-8:15 PM (PT)) (3)
aTTP Oral Presentation at ASH:
- Integrated Efficacy Results from the Phase II and Phase III Randomized Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (abstract number 373; oral presentation on Sunday, December 2, 2018: 12:00-1:30 PM (PT))
Advancements in Rare Genetic ConditionsSanofi Genzyme has worked in rare genetic conditions, including Gaucher disease for more than 30 years. Gaucher disease is an inherited genetic condition that can affect the blood, organs and bones. Because Gaucher disease has similar signs and symptoms of some more common hematologic malignancies, it is often misdiagnosed. Data presented at ASH includes oral eliglustat for the treatment of Gaucher disease type 1.
Gaucher Disease Presentations at ASH:
- Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials (abstract 2396; poster on Sunday, December 2, 6:00-8:00 PM (PT))
- The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials (abstract 3692; poster on Monday, December 3, 6:00-8:00 PM (PT))
Isatuximab and BIVV001 are investigational agents and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency worldwide for the use under investigation.
The U.S. FDA has accepted for priority review the Biologics License Application for caplacizumab for treatment of patients 18 years of age and older experiencing an episode of aTTP. The European Commission approved caplacizumab as the first therapeutic specifically indicated for the treatment aTTP earlier this year.
About SanofiSanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life
1. Bioverativ, a Sanofi company, and Sangamo Therapeutics, Inc. have an exclusive worldwide collaboration to develop and commercialize ZFN-mediated gene-edited cell therapies for the treatment of beta thalassemia and sickle cell disease.
2. Bioverativ, a Sanofi company, is responsible for the development of BIVV001
3. Bioverativ, a Sanofi company, and Sobi collaborate on the development and commercialization of rFVIIIFc and rFIXFc